beta3-Adrenergic Agonist Drug Class List

Drugs in Drug Class: beta3-Adrenergic Agonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes				Y
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes			Y	Y
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes

Last updated: June 10, 2026

Executive summary

Beta3-adrenergic agonists compete in a concentrated IP and regulatory landscape dominated by (1) molecule-level composition-of-matter (CoM) estates for individual agents, (2) formulation and method-of-use patents tied to urologic or metabolic indications, and (3) FDA exclusivity that can delay generic or biosimilar-style competition even when patents expire. Market dynamics are shaped by where each beta3 agonist sits across indications (overactive bladder/urinary retention vs. obesity/metabolic targets vs. other off-label routes), the route of administration (oral vs. topical/extended-release), and whether the lead product’s exclusivity is backed by Orange Book listings and enforceable patent claims. For investors and licensing teams, the critical work is mapping (a) Orange Book patent families by NDA and dosage form, (b) expiration sequencing by jurisdiction, (c) Paragraph IV challenge history, and (d) settlement and at-risk launch dates, then stress-testing whether “evergreening” patents on extended-release or dosing regimens block practical generic entry.

Beta3-adrenergic agonist market overview: where do sales and competition cluster?

Featured snippet answer: Beta3-adrenergic agonist commercial competition clusters around specific approved indications and delivery forms, with urologic oral extended-release products typically showing the highest patent thicket intensity from formulation and dosing regimen IP.

Which therapeutic areas anchor beta3 agonists?

Common beta3-adrenergic agonist market clusters by indication include:

• Urology: overactive bladder, urinary urgency, urge incontinence, and related symptom control.
• Metabolic/weight management: obesity and metabolic targets (where pursued), typically with longer-term development and tighter differentiation through PK/PD and dose-response.
• Other smooth muscle applications: less standardized commercialization patterns depending on sponsor strategy and trial outcomes.

What drives market dynamics?

Key commercial drivers that also correlate with patent strategy:

• Formulation differentiation: extended-release and solubility/particle engineering often generate additional patent families even after CoM expiry.
• Dose regimen lock-in: method-of-use and dosing frequency patents are used to protect clinical protocols.
• Payer and guideline adoption: product positioning can outlast early IP losses through contracting and formulary placement, but generic entrants compress net pricing once non-infringing substitutes launch.
• Manufacturing/IP barriers: process patents, especially for controlled-release and crystalline forms, can delay launch even with acceptable bioequivalence.

Competition model for beta3 agonists: what do incumbents defend?

Incumbents typically defend market share through a layered estate:

1. CoM patents on the active molecule (core expiry driver).
2. Polymorph/solid-state patents (salt forms, crystal forms).
3. Formulation patents (ER matrices, coating, stabilizers).
4. Method-of-use patents (specific indication, patient subsets, dosing schedules).

What patents protect beta3-adrenergic agonists?

Featured snippet answer: The patent estate for beta3-adrenergic agonists is usually dominated by CoM patents for the active pharmaceutical ingredient plus separate formulation and method-of-use families tied to approved dosing and release profiles.

How patent coverage is typically structured

For a beta3-adrenergic agonist product, the enforceable estate generally breaks into these claim categories:

• Composition of matter
  • API per se
  • salts, hydrates, solvates
  • specific stereochemistry and polymorphs
• Pharmaceutical compositions
  • dosage form compositions
  • ER or delayed-release formulations
  • particle size and excipient systems
• Methods of use
  • treating a defined indication
  • dosing regimen frequency
  • patient populations and symptom measures
• Manufacturing/process
  • specific crystallization or granulation steps
  • ER tablet/capsule manufacturing processes

Patent strength levers that matter for freedom-to-operate

• Claim breadth: CoM patents are usually broader than formulation-specific patents, but formulation patents can still block commercially relevant generics if claims are tight around release kinetics and excipient systems.
• Claim timing: method-of-use patents can remain enforceable even when a generic can avoid CoM if the generic product would infringe the method claims through label-directed use.
• Orange Book listing scope: enforceability for US generic entry depends on what is listed for the NDA and what claims are asserted in litigation.

Geographic coverage: where enforcement tends to matter most

• US: Orange Book listing and Hatch-Waxman litigation structure determine generic timing.
• Europe (EP/UPC): claim quality, translation constraints, and Unified Patent Court strategy can alter leverage.
• UK: post-Brexit validation and court posture shape outcomes.
• Japan and key Asian markets: where follow-on patents can still be enforceable if filing dates support term.

When does beta3-adrenergic agonist exclusivity end?

Featured snippet answer: Exclusivity can extend competition beyond patent expiration through FDA exclusivity periods tied to the NDA and lifecycle events; the effective end date for market exclusivity is the later of patent expiry and exclusivity end, per the product’s Orange Book and FDA exclusivity records.

Patent term vs. FDA exclusivity: how timelines are sequenced

For oral small-molecule beta3 agonists in the US, the practical entry clock is:

1. End of regulatory exclusivity (NCE exclusivity, new clinical investigation exclusivity, or other FDA exclusivity types tied to the NDA and supplements).
2. Expiration of listed patents in the Orange Book for the specific dosage form.
3. Litigation stay and settlement terms after a Paragraph IV filing.

Key exclusivity timing inputs for market models

• NCE status (if applicable) and whether the drug qualifies for 5-year exclusivity.
• 3-year exclusivity triggers for line extensions.
• Patent term adjustment and pediatric exclusivity (where applicable).
• Number of listed patents per NDA and whether they form a “last-to-expire” set.

What Orange Book status applies to beta3-adrenergic agonist products?

Featured snippet answer: Orange Book status dictates what patents are “for the NDA” and therefore what Paragraph IV filers must address; it also defines which patents can trigger litigation-driven stays.

How to interpret Orange Book listings for beta3 agonists

Market teams should map:

• NDA holder and label dosage form
• Each listed patent number
• Patent category (CoM, formulation, method-of-use, etc.)
• Expiration date
• Whether the patent is tied to one formulation strength or multiple
• Whether there are multiple Orange Book “late” patents that control launch timing

What listing patterns usually signal a thicker estate?

• Multiple patent listings expiring in staggered years.
• A final “last-to-expire” method-of-use patent close to the molecule expiry.
• Multiple formulation patents for ER vs immediate-release variants.

How many patents cover beta3-adrenergic agonists by product and dosage form?

Featured snippet answer: Beta3-adrenergic agonist products often have multi-family estates with several dozen Orange Book entries across CoM, formulation, and method-of-use, with dosage-form-specific patents being a major driver.

How to count patents in a way that predicts launch risk

Two useful counts:

• Orange Book entries per NDA and strength: the litigable perimeter for Paragraph IV.
• Independent inventive families per product: clusters of related patents that can be invalidated together.

What “high risk” looks like in launch analytics

• High density of formulation and method-of-use patents expiring late.
• Multiple overlapping ER formulation claims that constrain non-infringing design-around.
• Patent families with prior claim construction history favoring the patentee.

Which beta3-adrenergic agonists have Paragraph IV challenges, and who filed them?

Featured snippet answer: Paragraph IV challenges are the primary signal for imminent generic entry; the most material market impact comes from (1) which NDA and dosage form is targeted, (2) how many listed patents are challenged, and (3) settlement and court outcomes that determine effective entry dates.

How to analyze Paragraph IV impact

A practical market map includes:

• ANDA filer: identity and any repeat litigant behavior.
• Orange Book patents challenged: counts and categories.
• Requested relief: whether the filer aims for launch at risk or after settlement.
• Court jurisdiction and case number: track injunction risk and stay terms.
• Settlement triggers: agreed entry date or license terms.

Settlement agreements: what to model commercially

In beta3 agonists, settlements commonly include:

• Agreed launch date for the generic manufacturer.
• Royalty or license economics (if structured as delayed entry licensing).
• Design-around constraints (limits on formulation or label carve-outs).

What patent litigation affects beta3-adrenergic agonists?

Featured snippet answer: Litigation affects launch timing primarily through automatic stays tied to Paragraph IV filings and through court-enforced injunctions on specific Orange Book-listed claims.

Litigation variables that move generic entry

• Preliminary injunction outcomes: determine whether a launch is blocked even after a court decision.
• Final invalidity or non-infringement findings: determine if a generic can launch safely without appeal.
• Appeal timelines: can extend stays beyond initial judgments.
• Claim construction: affects whether design-arounds remain non-infringing.

How to translate litigation outcomes into “at-risk launch probability”

Market teams usually categorize:

• Patents likely to be upheld: high risk of injunction.
• Patents likely invalidated: risk shifts toward “appeals and delays” rather than permanent blocking.
• Settlement likely: probability rises where overlapping commercial interests create near-term licensing economics.

How do beta3-adrenergic agonists compare on patent estate risk?

Featured snippet answer: Patent estate risk depends less on the therapeutic class label and more on product-specific lifecycle choices: extended-release formulation strategy, method-of-use claims tied to the label, and the timing of last-to-expire patents.

Comparative framework: what to benchmark across molecules

For each beta3 agonist product, build a matrix:

• Active ingredient CoM expiry
• Last formulation patent expiry
• Last method-of-use expiry
• Number of Orange Book entries per dosage form
• History of Paragraph IV challenges
• Settlement/entry dates
• Exclusivity events beyond patents

Typical outcomes

• CoM-heavy estates: generic risk accelerates near molecule expiry if formulation and method-of-use claims are sparse.
• evergreening-heavy estates: generic entry remains blocked by formulation/method-of-use patents even after CoM expiry.

What formulations are protected by beta3-adrenergic agonist patents?

Featured snippet answer: Formulation protection typically centers on extended-release release profiles, excipient systems, coatings, and solid-state properties that support the approved dosing regimen.

Formulation patent categories to look for

• ER matrix/coating systems
• Delayed-release mechanisms
• Solubility and particle engineering
• Stabilization and moisture protection
• Encapsulation or tablet engineering

Why formulation patents matter in Hatch-Waxman

Even if a generic matches the API, it must also meet claim restrictions in formulation patents and must avoid infringement via:

• non-infringing excipient substitutions
• altered release kinetics (if permitted by label bioequivalence)
• different solid-state forms not covered by claims

What method-of-use patents cover beta3-adrenergic agonists?

Featured snippet answer: Method-of-use patents typically cover treating a specified indication with defined dosing schedules and sometimes defined patient populations.

Common method-of-use claim targets

• Treating overactive bladder symptoms including urgency and frequency.
• Treating urge incontinence.
• Dosing regimens aligned to label instructions (dose strength and frequency).
• In some portfolios, combination regimens or sequential therapy.

How method-of-use affects generic entry

Generic “label design” can sometimes mitigate risk if the label is carved out from patented method claims. In practice, enforceability depends on:

• whether the claim reads on label-directed use
• whether the generic can offer a carve-out without losing bioequivalence relevance or market access

What generic entry risks exist for beta3-adrenergic agonists?

Featured snippet answer: Generic entry risk is highest when multiple late-expiring formulation and method-of-use patents have no clear design-around path and when litigation indicates enforceable claim constructions.

Primary entry risk scenarios

1. At-risk launch after Paragraph IV wins or after settlement lifts the stay.
2. Delayed launch due to settlement or appeal.
3. Partial entry with carve-outs that reduce infringement exposure but can limit market uptake.

Practical non-infringing design strategies

When formulation claims are broad, generic teams may attempt:

• different release profiles while staying within bioequivalence thresholds
• alternate solid-state forms (when allowed by patent scope)
• avoiding infringement of specific excipient system claims

How does FDA regulatory status shape beta3-adrenergic agonist competition?

Featured snippet answer: FDA status drives the feasible competitive pathways, including ANDA for small molecules and exclusivity-driven barriers; for each product, pathway type determines timing and what “at risk” means.

Pathway implications for market timing

• 505(b)(2) route: often used for reformulations; may carry different exclusivity and patent linkage effects.
• ANDA: standard for generic entry; requires bioequivalence and patent certifications.
• 505(j): for abbreviated pathways when applicable.

Label and exclusivity interplay

• If a drug’s label includes patented method-of-use claims, the label determines infringement risk for generics.
• If exclusivity blocks approval, even a non-infringing ANDA can face timing delays.

Which companies lead beta3-adrenergic agonist development and what is the competitive landscape?

Featured snippet answer: Leadership tends to concentrate among sponsors with integrated formulation and lifecycle IP strategies, while generics target specific dosage forms where Orange Book listings and litigation stances are most favorable.

Competitive map by role

• Originators: hold CoM, formulation, and method-of-use estates for their marketed NDA products.
• Generic challengers: target Orange Book patents through Paragraph IV certifications.
• Lifecycle innovators: pursue 505(b)(2) reformulations or alternative dosing to differentiate clinically and commercially.

What revenue exposure exists from beta3-adrenergic agonist patent cliffs?

Featured snippet answer: Revenue exposure peaks around the “last-to-expire” patent date for the marketed NDA and dosage form, with incremental exposure from late formulation and method-of-use patents that can keep a product off the shelf for generics even after CoM expiry.

Modeling revenue sensitivity

For each product, model:

• peak exclusivity window (between major patent expiry clusters)
• probability-weighted entry outcomes based on:
  • litigation posture
  • settlement likelihood
  • generic readiness

Key Takeaways

• Beta3-adrenergic agonist competition is governed by layered IP: CoM, formulation, and method-of-use patents that map to Orange Book listings by NDA and dosage form.
• Generic entry is not controlled by the molecule alone; late-expiring formulation and method-of-use patents often determine the effective launch window.
• Market timing depends on the sequence of patent expiry, FDA exclusivity, and Paragraph IV litigation stays and settlements.
• The highest launch risk arises where multiple late patents are categorized such that design-around is difficult and label-directed use triggers method-of-use infringement concerns.
• A product-by-product Orange Book map is the necessary basis for any licensing, FTO, or investment decision in this class.

FAQs

1. How do I identify the “last-to-expire” patent for a beta3-adrenergic agonist NDA?
2. What Orange Book patent categories usually create the biggest generic entry barriers for beta3 agonists?
3. How do formulation patents in extended-release beta3 agonists impact bioequivalence-based generic launches?
4. When do method-of-use patents on beta3 agonists remain enforceable against generics with a similar label?
5. What settlement structures most often determine the effective generic entry date for beta3-adrenergic agonists?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. U.S. FDA. Drug Approval and/or Therapeutic Equivalence (Orange Book) and exclusivity resources.
3. U.S. Code. Hatch-Waxman Act provisions on patent certification and exclusivity (21 U.S.C. § 355).
4. U.S. Patent and Trademark Office and related practice guidance on patent term adjustments and extensions.